Table 2 Comparison of baseline characteristics of patients with low (Q1–3) vs. high (Q4) MEF2C expression

Median age, years (range)

10.55 (0.01–29.8)

6.9 (0.06–19.8)

<0.001

Male sex, n (%)

279 (50 %)

95 (51 %)

0.817

WBC (×10³/μL), median (range)

30.7 (0.2–827.2)

20.9 (0.5–519.0)

0.160

Median bone marrow blasts, %

67.5 (0–100)

71 (3–100)

0.038

Platelet count (×10³/μL), median (range)

48 (4–556)

48 (1–11,177)

0.484

Hemoglobin (g/dL), median (range)

8.1 (2.3–17.0)

8.1 (1.8–17.0)

0.684

Cytogenetics, n (%)

 Normal

142 (26 %)

21 (12 %)

<0.001

 t(8;21)(q22;q22)

101 (18 %)

10 (6 %)

<0.001

 inv(16)/t(16;16)(p13.1;q22)

78 (14 %)

12 (7 %)

0.007

 t(9;11)(p22;q23) or other abn 11q23

87 (16 %)

67 (37 %)

<0.001

 t(6;9)(p23;q34)

10 (2 %)

1 (1 %)

0.309

 Monosomy 7

3 (1 %)

11 (6 %)

<0.001

 Del7q

4 (1 %)

2 (1 %)

0.642

 −5/5q−

6 (2 %)

4 (2 %)

0.275

 Trisomy 8

28 (5 %)

19 (10 %)

0.011

 Other

89 (16 %)

34 (19 %)

0.428

 Unknown

15

7

Risk group, n (%)

 Standard

230 (42 %)

123 (68 %)

<0.001

 Low

255 (46 %)

29 (16 %)

<0.001

 High

69 (12 %)

30 (16 %)

0.170

 Unknown

9

6

Molecular alterations, %

  FLT3/ITD

18 %

10 %

0.018

  NPM1 mutation

9 %

3 %

0.010

  CEBPA mutation

7 %

1 %

0.002

  WT1 mutation

6 %

5 %

0.688

Hepatomegaly, %

25 %

36 %

0.006

Splenomegaly, %

25 %

39 %

<0.001

Extramedullary disease, %

15 %

11 %

0.196

CNS disease, %

6 %

9 %

0.239

Chloroma, %

15 %

12 %

0.496

Treatment arm, n (%)

0.689

 Arm A—no GO

281 (50 %)

97 (52 %)

 Arm B—with GO

282 (50 %)

91 (48 %)